Singular Genomics Systems, Inc. to Present at the 42nd Annual Cowen Health Care Conference

Rhea-AI Summary

Singular Genomics Systems, Inc. (Nasdaq: OMIC) will present virtually at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 11:10 a.m. PT / 2:10 p.m. ET. The management team will participate in a fireside chat, inviting investors to access live and recorded webcasts via the company's investor relations website. Singular Genomics focuses on next-generation sequencing (NGS) and multiomics technologies, with products aimed at enhancing research and clinical applications. Their G4 and PX instruments target significant advancements in genomics and proteomics.

LA JOLLA, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 42^nd Annual Cowen Health Care Conference.

Singular Genomics’ management is scheduled to participate in a fireside chat Monday, March 7, 2022, at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.

Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company’s investor relations website at https://investor.singulargenomics.com/news-events/event-calendar.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products as well as our core product tenets: power, speed, flexibility, and accuracy. We are currently developing two products that are purpose built to target applications in which these core product tenets matter most. Our first product, the G4, targets the NGS market. Our second product in development, the PX, combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument to offer a versatile multiomics solution.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Singular Genomics present at the Cowen Health Care Conference?

Singular Genomics will present on March 7, 2022, at 11:10 a.m. PT / 2:10 p.m. ET.

How can I access the webcast for Singular Genomics' presentation?

Investors can access the live and recorded webcast on the company’s investor relations website.

What technologies does Singular Genomics specialize in?

Singular Genomics specializes in next-generation sequencing (NGS) and multiomics technologies.

What products is Singular Genomics currently developing?

Singular Genomics is developing the G4, targeting the NGS market, and the PX, which offers a multiomics solution.

What is the mission of Singular Genomics?

The mission of Singular Genomics is to accelerate genomics for the advancement of science and medicine.